Clinical Trial

A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing F182112 with Standard of Care in Patients with Relapsed or Refractory Multiple Myeloma
Trial Details
NCT Number NCT07579234
Lead Sponsor Shandong New Time Pharmaceutical Co., LTD
Conditions Relapsed or Refractory Multiple Myeloma (RRMM)
Enrollment 261 participants
Start Date 2026-01-25
Primary Completion 2029-01-25 (estimated)
Study Completion 2029-01-25 (estimated)
Updated on ClinicalTrials.gov 2026-05-12